Allergan Inc of Irvine, CA (maker of Botox and Juvederm) has reportedly filed a patent-infringement lawsuit against a Canadian drug company that is attempting to manufacture and market a generic version of Latisse.
The relevant patents for Latisse expire “as late as mid-2024,” reports Fox News. But Apotex Inc seeks to challenge those patents, allegedly claiming that two Latisse patents are neither valid nor enforceable. The company went so far as to file an application with the FDA to create and market a generic version of Latisse. Continue reading